UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: September 2025
Commission file number: 001-41557
CLEARMIND
MEDICINE INC.
(Translation of registrant’s name into English)
101 – 1220 West 6th Avenue
Vancouver, British Columbia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
CONTENTS
Attached hereto and incorporated herein is the
Registrant’s press release issued on September 25, 2025, titled “Clearmind Medicine’s Convenes Inaugural Scientific
Advisory Board Meeting to Advance Psychedelic-Derived Therapies”.
EXHIBIT INDEX
| Exhibit No. |
|
|
| 99.1 |
|
Press release titled: “Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies” |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
Clearmind Medicine, Inc. |
| |
|
| |
(Registrant) |
| |
|
|
| Date: September 25, 2025 |
By: |
/s/ Adi Zuloff-Shani |
| |
Name: |
Adi Zuloff-Shani |
| |
Title: |
Chief Executive Officer |
3
